Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma
Yago Nieto, Benigno C. Valdez, Peter F. Thall, Roy B. Jones, Wei Wei, Alan Myers, Chitra Hosing, Sairah Ahmed, Uday Popat, Elizabeth J. Shpall, Muzaffar Qazilbash, Alison Gulbis, Paolo Anderlini, Nina Shah, Qaiser Bashir, Amin Alousi, Yasuhiro Oki, Michelle Fanale, Bouthaina Dabaja, Chelsea Pinnix, Richard Champlin and Borje S. Andersson
Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30100
With the objective of developing more active high-dose chemotherapy for patients with refractory or high-risk relapsed lymphomas, infusional gemcitabine/busulfan/melphalan is combined with vorinostat and azacitidine (which enhanced antitumor activity in preclinical work). This clinical trial demonstrates that double epigenetic modulation of high-dose chemotherapy is safe and highly active in patients with refractory lymphomas.